P2X₇ receptor inhibitors. Claim 1: A compound of formula (1) wherein R¹ is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl or 5-membered heteroaryl, each of which is optionally substituted with one or more C₁₋₆ alkyl,halogen, hydroxy, C₁₋₆ hydroxyalkyl,Calcium fluoride c8321c83318324；C₃₋₆ cycloalkyl,C₁₋₄ alkoxy,Hydrogen fluoride c83218c83183242；ciano o -SO RR2 is cycloquilo c2238331； 832626；C₃₋₆ cyclohetalkyl,Calcium fluoride c8321c83318324；Hydrogen fluoride c83218c83183242；C₁₋₄ alkoxy,C₁₋₆ alkenyl,C₁₋₆ alkynyl,6-membered heteroaryl, phenyl or C₁₋₄ alkyl optionally substituted with one or more R⁹；R3: hydrogen, fluorine, tar c83318324；or where R² and R³ combine with the carbon to which they are attached to form cyclohexyl, tetrahydropyranyl, piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, azetidinyl, homomorpholinyl, homopiperidinyl or homopiperazinyl, each of which is optionally substituted with one or more alkyl₁ ₋₆,C₁₋₆ alkenyl,C₃₋₆ cycloalkyl,C₁₋₆ alkoxy,Oxo, - nr8310； - r8311o fluorine, wherein r830808 is halogen, and c83218c83318324 is fluorinated；ciano ciclopropilo alquiloxi CCalcium fluoride Xi c8321c83318324；-SO₂R⁸,-8310； - lessor 8311 or 832183；where R⁵ is halogen, C₁₋₆ alkyl,Calcium fluoride c8321c83318324；ciano -SO R-8310； 8311；C₁₋₆ alkoxy,a. Fluorescence oalcoxi c83216c83318324；where R⁶ and R⁷ independently of each other are hydrogen or C₁₋₆ alkyl；where R⁸ is C₁₋₆ alkyl,C₃₋₆ cycloalkyl is C₁₋₄ fluoroalkyl；R8313 is the lessor of c8332131；C₃₋₆ cycloalkyl,-No. 830404； R1,C₁₋₄ fluoroalkyl or 3- to 7-membered heterocyclyl which is optionally substituted with one or more C₁₋₆ alkyl,Halogen, hydroxy, calcium fluoride c8321；C₃₋₆ cycloalkyl,C₁₋₄ alkoxy,e. Fluorinated oalcoxi c831832421；O R1 83044 and R1 are combined with the nitrogen which is connected to form piperazinilo, piperidiilo, morfoline, pirrolidini, azetidini, homamopolinil, homapiridinilo or homapippiperazine. Each substance can be replaced by one or more c83318326 tar；C₁₋₆ alkoxy,Oxo o o FL o
